PFE vs WHWK
PFE: Global biopharmaceutical company discovering, developing, and manufacturing prescription medicines and vaccines across oncology, immunology, cardiovascular, and infectious disease. WHWK: Clinical-stage oncology company developing next-generation antibody-drug conjugates (ADCs) targeting validated tumor antigens with advanced linker-payload technology.
Side-by-side fundamentals
| Metric | PFE | WHWK | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $24.82 | $3.99 | |
| Market cap as of 2026-07-23 | $142.0B | $216M | |
| P/E as of 2026-07-23 | 18.96 | n/a | |
| PEG as of 2026-07-23 | -3.38 | n/a | |
| Net margin as of 2026-07-23 | +11.8% | +99.4% | WHWK higher |
| Gross margin as of 2026-07-23 | +74.8% | +88.7% | WHWK higher |
| Operating margin as of 2026-07-23 | +15.4% | +87.4% | WHWK higher |
| ROE as of 2026-07-23 | +8.4% | -79.6% | PFE higher |
| ROA as of 2026-07-23 | +3.6% | -74.0% | PFE higher |
| Debt / equity as of 2026-07-23 | 0.72 | 0.00 | WHWK lower |
| Revenue growth (YoY) as of 2026-07-23 | +1.4% | -22.3% | PFE higher |
| Revenue CAGR (3y) SEC XBRL | -14.8% | -22.3% | PFE higher |
| Dividend yield as of 2026-07-23 | +6.9% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-23 | 0.28 | 0.81 | |
| 1-year return as of 2026-07-22 close | -1.3% | +113.4% | WHWK higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.